ALAN LE: Open Payments
NPI 1891356671 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,421 in 115 payments from 9 companies in 2025. Trend: 2023 $1,408 · 2024 $2,571 · 2025 $4,421
Food & beverage: $3,633Consulting: $740Travel & lodging: $48
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $1,660 |
| Alkermes, Inc. | 29 | $540 |
| Teva Pharmaceuticals USA, Inc. | 8 | $442 |
| Neurocrine BioSciences, Inc. | 13 | $422 |
| Otsuka America Pharmaceutical, Inc. | 12 | $385 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $313 |
| Axsome Therapeutics, Inc. | 7 | $272 |
| ABBVIE INC. | 15 | $220 |
| Janssen Pharmaceuticals, Inc | 2 | $167 |
Products named: COBENFY, UZEDY, INGREZZA, ARISTADA, CAPLYTA, ABILIFY MAINTENA, Auvelity, VRAYLAR.
Industry payments across CA — which companies pay providers there.
